

## A Probable Case of Burn-out NASH Caused by Panhypopituitarism Secondary to Craniopharyngioma

Terawaki, Yuichi

Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University

Murase, Kunitaka

Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University

Motonaga, Ryoko

Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University

Tanabe, Makito

Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University

他

<https://doi.org/10.15017/1661293>

---

出版情報：福岡醫學雑誌. 107 (3), pp.53-61, 2016-03-25. Fukuoka Medical Association  
バージョン：  
権利関係：

---

## Case Report

---

### A Probable Case of Burn-out NASH Caused by Panhypopituitarism Secondary to Craniopharyngioma

Yuichi TERAWAKI<sup>1)</sup>, Kunitaka MURASE<sup>1)</sup>, Ryoko MOTONAGA<sup>1)</sup>, Makito TANABE<sup>1)</sup>  
Takashi NOMIYAMA<sup>1)</sup>, Satoshi SHAKADO<sup>2)</sup>, Mikiro MIZOGUCHI<sup>3)</sup>, Shotaro SAKISAKA<sup>2)</sup>  
and Toshihiko YANASE<sup>1)\*</sup>

<sup>1)</sup> Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University

<sup>2)</sup> Department of Gastroenterology and Medicine, School of Medicine, Fukuoka University

<sup>3)</sup> Department of Pathology, Faculty of Medicine, Fukuoka University

#### Abstract

A 38-year-old man diagnosed with craniopharyngioma at 8 years old underwent repeated surgery and radiation therapy. Complications included panhypopituitarism including growth hormone deficiency and hypogonadism at 13 years old. At 26 years of age, a slight fatty liver was found, which finally developed into liver cirrhosis (LC) at 35 years old. Viral infection or other etiologies causing LC were negative on serum examinations. Liver biopsy suggested a possibility of burn-out non-alcoholic steatohepatitis. This case indicates that a long-standing growth hormone deficiency and hypogonadism may lead to LC as a type of burn-out non-alcoholic steatohepatitis.

**Key words :** Craniopharyngioma · Panhypopituitarism · Liver cirrhosis · Growth hormone deficiency · Non-alcoholic steatohepatitis · Non-alcoholic fatty liver disease

#### Introduction

Although pathologically benign, craniopharyngioma grows and progresses to adjacent tissues such as cerebral parenchyma, the pituitary gland, and others<sup>1)</sup>. In addition, local inflammation via various inflammatory cytokines secreted by the craniopharyngioma causes strong adhesion to surrounding tissue, making it difficult to remove craniopharyngioma completely, thus leading to frequent recurrence of the tumor<sup>2)</sup>. Consequently, patients with panhypopituitarism, because of repeated surgery and radiation therapy, are often encountered.

Non-alcoholic fatty liver disease (NAFLD) is a broad term encompassing a broad spectrum of abnormalities of the liver including the accumulation of lipids within hepatocytes (fatty liver or hepatic steatosis), inflammation of the liver

(NASH), and finally liver cirrhosis (LC)<sup>3)</sup>. NASH eventually develops into hepatocellular carcinoma<sup>3)</sup>. The prevalence of NAFLD is thought to be rapidly increasing and associated strongly with the pandemic increase in obesity, type 2 diabetes mellitus, and insulin resistance<sup>3)4)</sup>. Importantly, visceral adiposity is a significant risk factor for the development of fibrosis associated with NAFLD<sup>5)</sup>.

Laboratory data are insufficient to make a diagnosis of hepatic steatosis and NASH<sup>6)</sup>. The gold standard for diagnosis is liver biopsy, and approximately 20–50% of healthy individuals assessed for partial liver donation have biopsy-proven hepatic steatosis<sup>7)8)</sup>. While the pathogenesis of NAFLD is complex, a three-hit hypothesis has been proposed<sup>4)</sup>. The accumulation of lipids, the initiation of an inflammatory response, and a defective repair and regenerative response are considered the three “hits”. Specifi-

---

\*Correspondence : Toshihiko YANASE, Department of Endocrinology and Diabetes Mellitus, School of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.  
E-mail : tyanase@fukuoka-u.ac.jp

cally, “the second hit”, oxidative stress, inflammatory cytokines, iron overload and others have been thought to trigger or cause hepatic death (the third hit).

NAFLD is often seen in patients with endocrine disorders including growth hormone deficiency (GHD), hypogonadism, hypothyroidism, and hypercortisolemia<sup>9–12)</sup>, but has often been overlooked, even by endocrinologists. Indeed, in Japan, few reports are available on NAFLD/NASH and endocrine disorders, and only two research papers from one group demonstrated NASH in association with GHD<sup>11)12)</sup>.

Here, we report the case of a 38-year-old man with LC and panhypopituitarism who had a history of repeated treatment for craniopharyngioma by surgery and radiation therapy. From this distinctive clinical course, long-standing GHD and hypogonadism were speculated to be the main cause of LC in this patient, likely via NASH.

### Case Report

A 38-year-old man first visited our hospital at 8 years of age because of headache, vomiting, and anoxia. Examinations led to a diagnosis of craniopharyngioma. He underwent surgery and received radiation therapy. However, the tumor relapsed six times and he underwent surgery every time. At 13 years of age, he was diagnosed with panhypopituitarism and since then he has taken hydrocortisone and levothyroxin. Presently, he takes hydrocortisone 20 mg twice daily and levothyroxine 100 $\mu$ g once daily. At 26 years of age, his serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were elevated, and he was subsequently diagnosed with a slight fatty liver by abdominal ultrasound. At 31 years of age, his maximum body weight was recorded (78.4 kg ; body mass index (BMI), 26.7 kg/m<sup>2</sup>). At 33 years of age, he was diagnosed with diabetes and abdominal ultrasound again showed fatty liver. Currently, he takes once-daily sitagliptin 50 mg and gliclazide 20 mg. At 34 years of age, his serum sodium level was elevated, but he was

asymptomatic. At 35 years of age, he was diagnosed with LC by abdominal ultrasound. At 38 years of age, his serum sodium level was 161 mEq/L and he was diagnosed with postoperative diabetes insipidus, administered desmopressin, and hospitalized to investigate endocrine function. The patient's physical examination revealed height, 171.4 cm ; weight, 59.6 kg ; BMI, 20.3 kg/m<sup>2</sup> ; blood pressure, 92/70 mmHg ; pulse, 65 bpm regular ; right complete blindness, and left temporal hemianopsia due to residual craniopharyngioma. He doesn't smoke and drink alcohol. The loss of pubic and axillary hair because of panhypopituitarism was also observed, but no Cushingoid feature was demonstrated. No abnormalities of the chest, abdomen, and nervous system were observed.

Endocrinological examination revealed complete panhypopituitarism including deficiencies of ACTH, TSH, PRL, GH, LH, and FSH. The secretion of these hormones was not stimulated by a combined test with CRH, TRH, GRH, and LH-RH. GH was not increased even after the GH-RP2 test and the peak value was less than 9 ng/mL, indicating a severe form of GHD (Table 2). The serum level of testosterone was also very low, indicating hypogonadotropic hypogonadism. Laboratory data and image analysis revealed thrombocytopenia, dull marginal liver and gastric varix was observed, suggesting the presence of LC (Fig. 1). During hospitalization, hypernatremia was improved by desmopressin. After hospitalization in our department, he was admitted to the Department of Gastroenterology to investigate the cause of LC and for treatment of esophageal varices (Fig. 2). Laboratory tests and past history indicated that LC was not caused by hepatitis B or C virus, alcohol, hemochromatosis, Wilson's disease, autoimmune hepatitis, or primary biliary cirrhosis (Table 1). His gastric varix was treated with sclerotherapy. Liver biopsy showed a mild inflammatory infiltrate and moderate fibrosis in the portal areas with Kupffer cell hyperplasia (Fig. 3).

**Table 1** Laboratory data

〈Complete blood count〉			〈Blood chemistry〉		
WBC	5.6	$\times 10^3/\mu\text{L}$	TP	7.1	g/dL
Neutrophil	46.1	%	Alb	3.9	g/dL
Eosinophil	2.0	%	T-Bil	0.3	mg/dL
Baso	0.4	%	AST	28	U/L
Lymphocyte	47.0	%	ALT	29	U/L
Monocyte	4.5	%	LDH	216	U/L
RBC	4.87	$\times 10^6/\mu\text{L}$	ALP	267	U/L
Hb	12.6	g/dl	$\gamma$ GTP	37	U/L
Ht	41.1	%	ChE	480	U/L
Plt	87	$\times 10^3/\mu\text{L}$	CK	48	U/L
					BUN 11 mg/dL
					Cr 0.9 mg/dL
					UA 5.7 mg/dL
					Na 152 mmol/L
					K 3.5 mmol/L
					Cl 113 mmol/L
					Ca 9.7 mg/dL
					TC 214 mg/dL
					TG 143 mg/dL
					HDL-C 44 mg/dL
					LDL-C 138 mg/dL
〈Endocrinology data〉			〈Diabetic data〉		
LH	<0.1	mIU/mL	HbA1c	7.5	%
FSH	<0.1	mIU/mL	BG	114	mg/dL
PRL	<1.0	ng/mL	insulin	12.9	$\mu\text{U/mL}$
GH	<0.03	ng/mL	CPR	2.75	ng/mL
IGF-1	10	ng/mL	Urine CPR	32.6	$\mu\text{g/day}$
(normal range 67–318 ng/mL)			24HCCr	88	mL/min
ACTH	<2.0	pg/mL	Anti-GAD	<0.3	U/mL
DHEA-S	<2	$\mu\text{g/dL}$	Antibody		
TSH	0.011	$\mu\text{IU/mL}$			
Total testosterone	8.0	ng/mL			
〈Laboratory data associated with hepatocyte〉					
HBs-Ag	(-)		Type IV		
HCV-Ab	(-)		Collagen 7S	5.9	ng/mL
PT	12.3s		(normal range $\leq 6.0\text{ng/mL}$ )		
PT-INR	1.10		IgG	1270	mg/dL
APTT	34.7s		IgM	86	mg/dL
Cu	122	$\mu\text{g/dL}$	Antinuclear		
Fe	91	$\mu\text{g/dL}$	antibody	7	Index
Ferritin	24	ng/mL	Anti-mitochondrial		
Hyaluronic acid	121.9	ng/mL	antibody	(-)	
(normal range $\leq 50\text{ng/mL}$ )			AFP	6.6	ng/mL
ceruloplasmin	27.2	mg/dL	PIVKA-II	17	mAU/mL

WBC, white blood cell ; RBC, red blood cell ; Hb, hemoglobin ; Ht, hematocrit ; Plt, platelet ; TP, total protein ; Alb, albumin ; T-Bil, total bilirubin ; AST, aspartate aminotransferase ; ALT, alanine aminotransferase ; LDH, lactate dehydrogenase ; ALP, alkali phosphatase ;  $\gamma$ GTP,  $\gamma$ -glutamyl transpeptidase ; ChE, cholinesterase ; CK, creatine kinase ; BUN, blood urea nitrogen ; Cr, creatine ; UA, uric acid ; Na, sodium ; TC, total cholesterol ; TG, triglyceride ; HDL-C, high density lipoprotein-cholesterol ; LDL-C, low density lipoprotein-cholesterol ; LH, luteinizing hormone ; FSH, follicle-stimulating hormone ; PRL, prolactin ; GH, growth hormone ; IGF-1, insulin-like growth factor 1 ; ACTH, adrenocorticotrophic hormone ; DHEA-S, dehydroepiandrosterone sulfate ; TSH, thyrotropin-stimulating hormone ; BG, blood glucose ; CPR, C-peptide immunoreactivity ; CCr, creatine clearance ; HBs-Ag, hepatitis B surface antibody ; HCV, hepatitis C virus ; PT, prothrombin time ; APTT, activated partial thromboplastin time ; Cu, copper ; Fe, iron ; AFP, alpha-fetoprotein ; PIVKA-II, protein induced by vitamin K antagonist-II.



**Table 2 A** LH-RH, TRH, GRH and CRH stimulation test

	pre	15'	30'	60'	90'
ACTH (pg/mL)	< 2.0	×	2.3	< 2.0	< 2.0
PRL (ng/mL)	< 1.0	< 1.0	< 1.0	< 1.0	< 1.0
GH (ng/mL)	< 0.03	×	< 0.03	< 0.03	< 0.03
LH (mIU/mL)	< 0.1	×	< 0.1	< 0.1	< 0.1
FSH (mIU/mL)	< 0.1	×	< 0.1	< 0.1	< 0.1
TSH ( $\mu$ IU/mL)	0.011	0.013	0.012	0.018	0.021


**Table 2 B** GHRP2 stimulation test

	pre	15 分	30 分	60 分	90 分
GH (ng/mL)	< 0.03	0.03	0.03	< 0.03	< 0.03

**Table 2** Endocrinological examinations

**A.** Provocation tests of GH, ACTH, LH, FSH, and TSH with growth hormone-releasing hormone (GRH), corticotropin-releasing hormone (CRH), luteinizing hormone-releasing hormone (LH-RH), and thyrotropin-releasing hormone (TRH).

**B.** Provocation test of GH secretion with growth hormone-releasing peptide 2 (GHRP2)




**Fig. 1** Abdominal simple computed tomography showing dullness of the marginal liver, swelling of the left lobe, and splenomegaly.


## Discussion

With regard to the cause of the patient's LC, laboratory tests and past medical history indicated that it was not caused by hepatitis B or C virus, alcohol, hemochromatosis, Wilson's disease, autoimmune hepatitis, or primary biliary cirrhosis. Thus, he was taken no drugs at diagnosed liver dysfunction, so it was not caused by drug hepatopathy. Based on the previous history of fatty liver, long history of panhypopituitarism as a

result of repeated treatment for craniopharyngioma, and the current endocrinological findings of GHD, the main cause of the patient's LC was suspected to be NASH secondary to adult GHD (AGHD) and/or hypogonadotropic hypogonadism<sup>9)</sup>. This patient's medication has included levothyroxine and hydrocortisone, thus ruling out the possibility of hypothyroidism as a cause of NASH by endocrinological disorders<sup>13)14)</sup>. In addition, hypercortisolemia as a cause of NASH<sup>15)16)</sup> can be ruled out from the absence of



**Fig. 2** Esophagogastroduodenoscopy showed esophageal varices in the lower esophagus without red color sign.



**Fig. 3** Liver biopsy showing a mild inflammatory infiltrate and moderate fibrosis in the portal areas with Kupffer cell hyperplasia. No malignant changes were observed. The black arrowheads indicate Kupffer cells. Surrounded the part by the black arrows suggests inflammatory cell infiltration.

Cushingoid features and no supporting biochemical data.

Pituitary hormone deficiencies occur most often in the following order ; growth hormone, gonadotropin, corticotropin, and thyrotropin. GHD occurs within 5 years after receiving external radiotherapy for pituitary tumors<sup>17)</sup>. In our case, considering that the patient was operated on and received radiation therapy at 8 years of age, and he was already receiving adrenal hormone and thyroid hormone administrations at 13 years of age after 5

years, we suggest that the onset of GHD was around 13 years of age. Previous cohort studies have shown that 7–21 years after the onset of NASH, LC can develop. The prevalence of developing LC from NASH is around 5–8%<sup>18)~20)</sup>, but little is known in the case of endocrinological etiologies. In our case, at least 25 years duration of panhypopituitarism seems to have been sufficient to lead to LC.

Because GH plays an important role in lipid metabolism, patients with AGHD are often

diagnosed with dyslipidemia<sup>21)</sup>. GH inhibits lipoprotein lipase activity in human adipose tissue<sup>22)</sup> and modulation of 11 $\beta$ -hydroxysteroid dehydrogenase isozymes<sup>23)</sup>. Nishizawa et al. reported that the prevalence of NAFLD in a GHD group significantly increased by 65% compared with healthy age-, sex-, and BMI-matched controls (77% vs. 12%,  $p < 0.01$ ), and the prevalence of NASH was 21% in patients with NAFLD in the GHD group compared with the prevalence of NASH of 1–3% for the Japanese population<sup>11)</sup>. The Janus kinase-2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) pathway is the main pathway involved in GH activity. In previous studies, attenuation of GH secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2<sup>24)</sup>, and loss of STAT5 leads to hepatosteatosis and impaired liver regeneration<sup>25)</sup>. From these findings, the loss of the GH-JAK2-STAT5 pathway may partly contribute to the pathogenesis of NAFLD. In addition, GH-independent IGF-1 action was also shown to be essential for the prevention of NASH in a GH-deficient rat model<sup>26)</sup>.

In Japan, GH-replacement therapy is adapted for severe AGHD. In a previous study, GH-replacement therapy led to a dramatic improvement in NASH associated with AGHD<sup>12)</sup>, thus it is possible that GH-replacement therapy may lead to prevention of NAFLD/NASH. However, in cases with recurrence of tumor and diabetes mellitus, GH-replacement therapy may not always be viable. Our case with repeated recurrence of craniopharyngioma and diabetes illustrated such a standpoint, making it difficult to perform GH replacement.

As well as GHD, hypogonadotropic hypogonadism was also an important cause of NAFLD in our case. Male hypogonadism due to testosterone deficiency is associated with obesity, metabolic syndrome, and diabetes<sup>9)27)28)</sup>. Mice specifically lacking the hepatic androgen receptor have been shown to have increased hepatic steatosis<sup>29)</sup>. The pathophysiology of metabolic disorders in testos-

terone deficiency involves not only androgen activity, but also estrogen deficiency because testosterone is converted to estrogens in peripheral tissue by aromatase. Translational studies have demonstrated an association between hepatic steatosis and low serum testosterone levels<sup>30)31)</sup>. Testosterone replacement in hypogonadal men causes a significant reduction in weight, BMI, waist circumference<sup>32)</sup>.

According to the two hit theory, the increase of inflammatory cytokines like Hs-CRP and interleukin 6 in AGHD<sup>33)</sup> and tumor necrosis factor alpha in testosterone deficiency<sup>34)</sup> may work as the second hit and may promote the development of NASH from simple steatosis.

The minimal criteria for the histological diagnosis of adult NASH include steatosis, hepatocyte injury, usually in the form of ballooning and apoptotic (acidophil) bodies, and lobular inflammation, typically localized in acinar zone 3. Fibrosis, as featured in other forms of chronic hepatitis, is not a required diagnostic feature of NASH<sup>35)</sup>. However, liver biopsy in our case showed a mild inflammatory infiltrate and moderate fibrosis in the portal areas with Kupffer cell hyperplasia, but not the above typical features. However, the histopathology of advanced NASH is not always stereotypical. Advanced liver fibrosis in NASH is often accompanied by a reduction in hepatic fat to the point of complete fat loss<sup>36)</sup>. The terminal pathology of NASH is called burn-out NASH in which a typical feature of NASH is not observed. Histopathology of our case was non-stereotypical, likely owing to burn-out NASH in which steatohepatitis may burn out leaving no evidence of NAFLD<sup>36)</sup>. In addition, there is a possibility that we could not obtain the typical lesion of NASH by needle biopsy.

In conclusion, we presented a case of panhypopituitarism due to craniopharyngioma, accompanied by LC. The cause of the patient's LC was thought to be NASH likely caused by long-term GHD and/or hypogonadotropic hypogonadism, though liver biopsy suggested a possibility of

burn-out NASH. Because detailed case reports of NAFLD due to panhypopituitarism including a liver biopsy are very rare in Japan, our case adds important information to the understanding of the pathophysiology of NASH caused by panhypopituitarism.

The authors state that they have no conflict of interest.

## REFERENCES

- 1) Kasai H, Hirano A, Llena JF and Kawamoto K : A histopathological study of craniopharyngioma with special reference to its stroma and surrounding tissue. *Brain Tumor Pathol* 14 : 41-45, 1997.
- 2) Mori M, Takeshima H and Kuratsu J : Expression of interleukin-6 in human craniopharyngiomas : a possible inducer of tumor-associated inflammation. *Int J Mol Med* 14 : 505-509, 2004.
- 3) Levene AP and Goldin RD : The epidemiology, pathogenesis and histopathology of fatty liver disease. *Histopathology* 61 : 141-152, 2012.
- 4) Dowman JK, Tomlinson JW and Newsome PN : Pathogenesis of non-alcoholic fatty liver disease. *QJM* 103 : 71-83, 2010.
- 5) Petta S, Amato MC, Di Marco V, Cammà C, Pizzolanti G, Barcellona MR, Cabibi D, Galluzzo A, Sinagra D, Giordano C and Craxi A : Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 35 : 238-247, 2012.
- 6) Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y and Okanoue T : Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD) : A simple clinical scoring system using ferritin, insulin, and type IV collagen 7S for predicting steatohepatitis nonalcoholic fatty liver disease. *J Gastroenterol* 46 : 257-268, 2011.
- 7) Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS and Suh DJ : Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea : a review of 589 consecutive liver biopsies in a single center. *J Hepatol* 47 : 239-244, 2007.
- 8) Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Olbrisch ME and Posner MP : Selection and outcome of living donors for adult to adult right lobe transplantation. *Transplantation* 69 : 2410-2415, 2000.
- 9) Little MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G and Sutton ML : Hypopituitarism following external radiotherapy for pituitary tumours in adults. *QJ Med* 70 : 145-160, 1989.
- 10) Hazlehurst JM and Tomlinson JW : Mechanisms in endocrinology : Non-alcoholic fatty liver disease in common endocrine disorders. *Eur J Endocrinol* 169 : R27-37, 2013.
- 11) Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, Yamamoto M, Suda K, Takahashi M, Seo Y, Yano Y, Kitazawa R, Kitazawa S, Koga M, Okimura Y, Chihara K and Takahashi Y : Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement. *Eur J Endocrinol* 167 : 67-74, 2012.
- 12) Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R, Imanaka M, Nishizawa H, Takahashi M, Seo Y, Hayashi Y, Kondo T, Okimura Y, Kaji H, Kitazawa R, Kitazawa S and Chihara K : Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. *Gastroenterology* 132 : 938-943, 2007.
- 13) Eshraghian A and Hamidian Jahromi A : Non-alcoholic fatty liver disease and thyroid dysfunction : A systematic review. *World J Gastroenterol* 20 : 8102-8109, 2014.
- 14) Pagadala MR, Zein CO, Dasarthy S, Yerian LM, Lopez R and McCullough AJ : Prevalence of hypothyroidism in nonalcoholic fatty liver disease. *Dig Dis Sci* 57 : 528-534, 2012.
- 15) Woods CP, Hazlehurst JM and Tomlinson JW : Glucocorticoids and non-alcoholic fatty liver disease. *J Steroid Biochem Mol Biol* 154 : 94-103, 2015.
- 16) Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L and Falezza G : Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. *Clin Endocrinol (Oxf)* 64 : 679-683, 2006.
- 17) Chung GE, Kim D, Kim W, Yim JY, Park MJ, Kim YJ, Yoon JH and Lee HS : Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. *J Hepatol* 57 : 150-156, 2012.
- 18) Little MD, Shalet SM and Beardwell CG : Radiation and hypothalamic-pituitary function. *Baillieres Clin Endocrinol Metab* 4 : 147-175,



- 1990.
- 19) Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A and Anqulo : The natural history of nonalcoholic fatty liver disease : a population-based cohort study. *Gastroenterology* 129 : 113–121, 2005.
- 20) Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G and Kechagias S : Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 44 : 865–873, 2006.
- 21) Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J and Hultcrantz R : Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. *Hepatology* 51 : 595–602, 2010.
- 22) Ito E, Hizuka N, Fukuda I and Takano K : Metabolic disorders in adult growth hormone deficiency : A study of 110 patients at a single institute in Japan. *Endocr J* 53 : 539–545, 2006.
- 23) Ottosson M, Vikman-Adolfsson K, Enerbäck S, Elander A, Björntorp P and Edén S : Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. *J Clin Endocrinol Metab* : 80 : 936–941, 1995.
- 24) Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Sheppard MC, Besser GM, Taylor NF and Stewart PM : Modulation of 11 $\beta$ -hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor : in vivo and in vitro studies. *J Clin Endocrinol Metab* : 84 : 4172–4177, 1999.
- 25) Sos BC, Harris C, Nordstrom SM, Tran JL, Balázs M, Caplazi P, Febbraio M, Applegate MA, Wagner KU and Weiss EJ : Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. *J Clin Invest* 121 : 1412–1423, 2011.
- 26) Cui Y, Hosui A, Sun R, Shen K, Gavrilova O, Chen W, Cam MC, Gao B, Robinson GW and Hennighausen L : Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. *Hepatology* 46 : 504–513, 2007.
- 27) Nishizawa H, Takahashi M, Fukuoka H, Iguchi G, Kitazawa R and Takahashi Y : GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. *Biochem Biophys Res Commun* 423 : 295–300, 2012.
- 28) Tanabe M, Akehi Y, Nomiyama T, Murakami J and Yanase T : Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men. *Endocr J* 62 : 123–132, 2015.
- 29) Zitzmann M : Testosterone deficiency, insulin resistance and the metabolic syndrome. *Nat Rev Endocrinol* 5 : 673–681, 2009.
- 30) Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, Hsu CL, Ma WL, Jokinen J, Sparks JD, Yeh S and Chang C : Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. *Hepatology* 47 : 1924–1935, 2008.
- 31) Kim S, Kwon H, Park JH, Cho B, Kim D, Oh SW, Lee CM and Choi HC : A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. *BMC Gastroenterology* 12 : 69, 2012.
- 32) Völzke H, Aumann N, Krebs A, Nauck M, Steveling A, Lerch MM, Roskopf D and Wallaschofski H : Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. *Int J Androl* 33 : 45–53, 2010.
- 33) Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N and Klibanski A : Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. *Annals of Internal Medicine* 133 : 111–122, 2000.
- 34) Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ and Saad F : Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome : the double-blinded placebo-controlled Moscow study. *Clin Endocrinol* 73 : 602–612, 2010.
- 35) Brunt EM, Kleiner DE, Wilson LA, Belt P and Neuschwander-Tetri BA : NASH Clinical Research Network (CRN) : Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD : distinct clinicopathologic meanings. *Hepatology* 53 : 810–820, 2011.
- 36) Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, Tokushige K and Shiratori K : Nonalcoholic steatohepatitis : cirrhosis, hepatocellular carcinoma and burnt-out NASH : *J Gastroenterol* 39 : 1215–1218, 2004.

(Received for publication January 27, 2016)

(和文抄録)

## 頭蓋咽頭腫の長期治療経過に伴う汎下垂体機能低下症により 肝硬変症をきたしたと考えられる一例

寺 脇 悠 一<sup>1)</sup>, 村 瀬 邦 崇<sup>1)</sup>, 元 永 綾 子<sup>1)</sup>, 田邊真紀人<sup>1)</sup>, 野見山 崇<sup>1)</sup>,  
釈迦堂 敏<sup>2)</sup>, 溝 口 幹 朗<sup>3)</sup>, 向坂彰太郎<sup>2)</sup>, 柳 瀬 敏 彦<sup>1)</sup>

<sup>1)</sup>福岡大学医学部内分泌・糖尿病内科

<sup>2)</sup>福岡大学医学部消化器内科

<sup>3)</sup>福岡大学医学部病理学

症例は38歳男性。8歳時に頭蓋咽頭腫と診断され、手術及び放射線療法がおこなわれた。その後も再発を繰り返し、13歳時には成長ホルモン分泌不全症及び性腺機能低下症を伴う汎下垂体機能低下症を認めた。26歳時に軽度の脂肪肝を指摘され、35歳時には肝硬変に至った。肝硬変を引き起こすようなウイルス性やその他の肝疾患は血液検査などから否定的であり、肝生検の結果はburn-out NASHが疑われた。本症例の長期経過から、汎下垂体機能低下症に伴う長期のGH分泌不全症に起因するNASHがその原因と推定された。